

## INDEX (Volume I)

## A

Abbotsford Cancer Centre (AC)	171
ABC transporters	129
Aboriginal heritage	164, 167
ABT-751	32, 43
ABVD	36
ACAPHA	38, 137
active surveillance	32
adaptation (sociobehavioural)	81
ADH-1	46
ADME studies	85
AEG 35156	43
aging	98, 102, 114
AHI-1	158, 162
alternative treatments	<i>see complementary</i>
aluminum workers	113
ALVAC-CEA/B7.1 Vaccine	44
amd 3100	33,34,37
AMG 162	24
AMG 412	35
AMN107	34
amonafile l-malate	37
amphotericin B	90
anastrozole	25, 26
androgen blockade	72
androgen independence	97, 99, 102, 104, 105, 132
anemia during therapy	39, 40, 45
angiogenesis	47, 54, 55, 90, 130, 143
imaging	89
vasculature	89, 90, 142
antibodies	<i>see monoclonal</i>
apoptosis (cell death)	54, 88, 90, 98, 103, 144, 156
arac	35
arm problems (lymphedema)	174
arrays	52, 116, 130, 132
microarray imaging	51, 53, 136
prognosis	99, 113
arry-334543	43
arsenic trioxide (As <sub>2</sub> O <sub>3</sub> )	36
assays, cell based	86, 144
autoimmunity	123, 183
autophagy	105
Avastin	27
AZD 0530	29
AZD 2171	32

## B

BAC arrays	103, 130, 131
BAY 43-9006	31
Bayesian methods (biostatistics)	115

BC Cancer Registry	107
Bevacizumab	25, 27, 28, 29, 39, 41
<i>see also monoclonal</i>	
bile acids	132
biliary cancer	27
bioinformatics	97, 101, 103, 104, 155
training	93, 97
biomarkers	47-8, 51, 54, 55, 85, 117, 130, 134, 137, 148, 182
biowarfare	131
bladder cancer	30
BLP 25	38
bms-354825	35, 36
bone density	26, 72
bone marrow failure	149, 162
bone marrow transplant	149
drug therapy	33-34, 37
laboratory research	144
bone metastases	24
bovine genome sequencing	93, 98
brachytherapy	63, 72
brain cancers	27, 112
<i>see also gliomas</i>	
BRCA1/2	59, 62, 124
breast cancer	
detection	26, 48, 58, 112, 117, 174, 182, 183
discoveries	6, 86, 89, 119
drug therapy	12, 23-26, 68, 88
genetics	7, 51, 52, 53, 104, 108, 116, 131, 147, 158, 183
imaging	86, 88, 183
laboratory research	6, 7, 48, 55, 89, 91, 105, 130, 147, 182, 184
prevention	24, 52, 61, 104, 111, 115, 118, 169
quality of life	14, 26, 80, 118, 174, 176, 183
radiotherapy	68-69
risk factors	112, 116, 169
sociobehavioural research	80, 81, 82, 84
survival	62
breast density	26, 61, 115, 118
<b>C</b>	
Caelyx	23, 34, 36, 41, 45
<i>see also doxorubicin</i>	
capacity building	8, 9, 47, 52, 58, 63, 70, 76, 97, 101, 107, 129-30, 133
Capecitabine	24, 27, 28, 32
Carboplatin	40, 41, 42, 43, 45
carcinogens	104, 111, 113, 116
cardiac cushion	143, 158
caregivers	76, 81, 82, 83, 168
carmustine	26
casodex	72

- CCI-779 32, 43, 45
- CDH1 *see E-cadherin*
- Celator Pharmaceuticals 86
- Celecoxib 24, 25
- C. elegans* 100  
*See nematode worm*
- cell phones 112, 116
- Centre of Excellence for Cancer Functional Imaging 63
- Centre for Health Economics in Cancer 108
- Centre for Translational and Applied Genomics (CTAG) 48, 147
- cervical cancer  
detection 11, 57, 61, 62, 134, 137  
molecular profiling 134
- cetuximab 27, 28, 29, 39
- Childhood / Young Adult Cancer Survivorship (CAYACS) 108, 112
- children 58, 176  
*see also pediatric, youth*
- Chinese / East Asian heritage 59, 62, 76, 79-80, 82, 83, 115, 119
- choice of treatment 32, 34, 119
- CHOP protocol 44
- CI-1033 23
- circadian rhythm 28
- cisplatin 30, 31, 33, 35, 38, 39, 40, 42, 70
- Clinical Trials Units 19, 63, 85
- Clodronate 68
- Cloretazine 35
- cnto 328 34
- colorectal cancer  
combined modality 89  
drug therapy 27-28  
genetics 100, 101  
phase 1 trials 44
- combined modality therapy 26, 27, 31, 33, 36, 38, 70, 89, 137
- communication 84, 113, 184
- Communities Oncology Network (CON) 163
- complementary therapy 62, 79-80, 175  
integration 79, 83, 176
- confocal micro/macroscopy 133, 136
- conformal radiotherapy, 3 dimensional 69, 71
- constipation 44
- continuity of care 167
- CP-714 /-724 43
- CPT-11 (irenotecan) 29, 40, 86, 89, 90, 91
- CPX-1 44
- Cryptococcus neoformans* 98
- culture 75, 76, 82-83, 167, 169, 184  
and screening 61, 79, 80, 111, 174  
language factors 115  
*see also language, specific heritage populations*
- Cyclophosphamide 23, 24, 26, 46
- cyclosporine 37
- cytarabine 35, 37
- cytogenetics 98
- cytometry 143, 144, 149, 155, 156
- cytotoxicity 161
- ## D
- dacarbazine 41
- darbepoetin alfa 45  
*see also epoetin*
- data analysis 58, 61, 62, 72, 76, 98, 100, 114
- decision making 80, 81, 84, 117, 119
- dendritic cells 123, 124
- Denosumab 24
- detection 9, 10, 47, 62, 124, 184  
technology 11, 53, 136, 138
- dexamethasone 34, 35, 73
- diet 84, 115  
education 58  
in prevention trials 69, 111
- differentiation 130
- diphtheria toxin - growth factor (DT-GF) 160
- Drug Discovery Research Program 85
- distance education 175
- D-L folinic acid 29
- DN101 31
- DNA *see genetic, gene, molecular*  
Methylation 7, 125, 131, 161, 184
- Docetaxel 23, 24, 25, 26, 30, 31, 33, 38, 39, 42, 43, 69, 72
- dosimetry 73
- double stranded break  
repair 115, 124  
surveillance genes 54, 100, 114
- doxil 34, 36
- doxorubicin 23, 29, 34, 41  
*see also Caelyx*
- drug therapy discoveries 85-92, 99  
*see also specific drug names and cancer types*
- dt 388il3 44
- ## E
- E-cadherin (CDH1) 52, 53, 132
- economics 62, 117, 166
- econazole 88, 89
- EGFR 41, 175
- EMSY gene 51, 52, 112
- endothelial cells 54, 143, 144
- epigenomic profiling 131
- Epirubicin 24, 26
- epithelial cells 143, 158

- EPO 906 42  
 Epoetin alfa 24, 40  
*see also darbepoetin*  
 Epothilone 24  
 Erlotinib 29, 39  
 estrogen receptors 147, 148, 184  
 Etoposide 38, 40  
 ETV6-NTRK3 148  
 Exemestane 24, 25, 26  
 exercise 26, 58, 182  
 extremely low frequency magnetic field (ELF-MF) 117
- F**  
 fibroblasts 91, 149  
 fiducial markers 72, 184  
 Filgrastim 24  
 5-fluorouracil 24, 26, 27, 28, 29  
 fluorescence imaging 114, 133, 134, 144  
 fludarabine 46  
 FOCAL study 58, 61  
 IV (four) edotecarin 26  
 fragmin 41  
 Fulvestrant 24
- G**  
 G-3139 *see oligonucleotides*  
 gastrointestinal cancers 53, 105  
*see also specific cancer types*  
 g-csf 33, 34  
 gemcitabine 29, 30, 35, 38, 39, 42, 90  
 gene amplification 51, 97, 112  
 gene-environment interactions 54, 100, 102, 104, 107, 114, 116, 117, 118  
 gene expression 41, 93, 97, 100, 104, 105, 121, 123, 124, 126, 134, 136, 142, 147, 155, 156, 157, 158, 161  
 gene identification and sequencing 52, 53, 98, 100, 101, 103, 105, 112, 116, 124  
 gene therapy 90, 157  
 genetic counselling 59, 62  
 Genetic Pathology Evaluation Centres (GPEC) 48  
 genetics research 124, 125-132, 142, 147, 155  
 bioinformatics 101, 104  
 prevention / screening 57, 102, 113  
*see also biomarkers, genome, molecule, proteomics*  
 genitourinary cancer 69-70  
*see also specific cancer types*  
 genomic profiling 47, 51, 53, 98, 102, 114, 123, 124, 130, 136  
 clinical trials 39  
 rearrangements 51, 53, 101, 102, 113, 115, 157  
 testing individuals 59, 118  
 whole genome 7, 100, 103, 116, 125-26, 132  
 germ cell cancer 33  
 gimatecan (LBQ 707) 43  
 gleevec 28, 36, 37  
 gliomas 26, 81  
*see also brain*  
 graft-versus-host disease 36, 37, 156  
 grapevines 102  
 growth factors  
*see palifermin, VEGF, ZD1839*  
 GTI-2040 31  
 GW 572016 26
- H**  
 HACE1 gene 148  
 haloperidol 168  
 haplotype 115  
 head and neck cancers 33, 70, 116  
 Healthy Living Schools program 58  
 heart failure 125  
 hematologic cancer *see leukemia, lymphoma*  
 hematopoiesis / hematopoietic cells 103, 144, 155, 156, 157, 158, 159, 162  
 Heparin 27  
 hepatocellular carcinoma 29  
 HER2  
 drug strategies 89  
 expression in tumours 88  
 target in clinical trials 41, 42, 43  
 Herceptin (trastuzumab) 23, 25, 26, 143  
 Hereditary Cancer Programs (HCP) 58-59, 62  
 herpes simplex virus (HSV) 158  
 Herzyme 42  
 hESC *see stem cells*  
 HGS-TR2 42  
 High Content Screening 86  
 hormone therapy 30, 31, 43, 69, 72  
*see also specific drugs*  
 hormones, blood levels 26  
 hospice 168  
*see also palliative*  
 HOX protein 103, 156  
 HOXB4 157  
 human papilloma virus (HPV) 58, 61, 104  
 hyperthermia drug release 92  
 hypoxia 90, 139, 144
- I**  
 idarubicin 90  
 IL-2 42  
 ILK 130, 132  
*see also kinases*

- imaging *see also PET*
- automated 133
  - computer algorithms 112
  - digital 51, 136
  - guidance systems 72
  - molecular 104, 117, 132, 136
  - MRI 86, 88
  - NIR 134
  - Ramen 134, 138
  - ultrasound 73
- imatinib mesylate (gleevec) 28, 36, 37
- immunoassays 184
- immunosuppression 124
- immunotherapy *see also vaccines*
- clinical trials 35, 36, 38, 44, 179
  - liposome vaccine 38
- InCELL analyzer 86
- Incidence *see detection, prevention*
- Indian / South Asian heritage 76, 84, 119, 174
- information needs 81, 84, 176
- insulin-like growth factor (IGF) 148
- insulin resistance
- breast cancer 61, 115
  - prostate cancer 114
- intensity modulated radiation therapy 72
- interferon alpha 32
- Investigational Drug Program (IDP) 19, 85
- Iodine I131 71
- Iranian heritage 76
- Irinotecan *see CPT-11*
- Iroflufen 29, 32
- islet cells 123, 1157
- isoniazid metabolism 101
- K**
- kidney cancer 32-33
- kinases 55, 147, 148,
- integrin linked (ILK) 125, 132, 158
- KT Interaction 76
- L**
- language
- interpreting 84, 177
  - ESL 115
- Lapatinib 24
- laser speckle imaging 113
- late effects 112
- lenalidomide 34
- Letrozole 23, 25, 26
- Leucovorin 27, 28
- leukemia
- drug therapy 34-37, 150
- laboratory research 155, 158, 160
- pediatric 149
  - phase 1 trials 44
  - risk factors, genetic 149, 150, 162
  - risk factors, lifestyle 112, 117
- LFA-1 161
- LHRH 175, 183
- lifestyle research 75, 80, 112, 117
- see also specific risk factors e.g. diet, tobacco*
- light-at-night 117
- liposomal drug delivery 89, 90, 91, 92
- in clinical trials 34, 36, 38, 41, 44, 45
- liver cancer 115
- Lomustine 26
- Lonafarnib 25
- lung cancer *see also tobacco*
- detection 134, 137
  - drug therapy 38-40, 136
  - genetics 7, 123, 131, 134, 136, 137
  - laboratory research 7, 123, 129, 132, 175
  - non-small cell 38-39, 132
  - phase 1 trials 44
  - prevention 137, 138
  - prognosis 132
  - radiotherapy 71
  - small cell 40
- Luven 32
- lymphatic transport 90
- lymphoma, Hodgkin 36, 47, 55
- lymphoma, non-Hodgkin
- drug therapy 13, 33-37
  - genetics 47, 51, 53, 54, 97, 100, 102, 108, 114
  - imaging 35
  - laboratory research 156
  - molecular studies 5, 129, 131, 155
  - phase 1 trials 42, 44
  - prevention 52, 54, 100, 104, 117
  - radiotherapy 71
- Lymphorad 131 71
- M**
- Mammalian Gene Collection project 103
- mammography 58, 115, 168
- mean glandular dose (MGD) 163, 168
- melanoma 108, 112, 113, 118
- melatonin 117
- mental retardation 102
- mercaptapurine 36
- mesenchymal transformation 143
- mesothelioma 41
- methotrexate 70
- Methylalntrexone (MNTX) 44
- MGCD0103 44

- microarrays *see arrays*
- midazolam 32
- mind influence on cancer 175
- mindfulness-based stress reduction 84, 177
- mitoxantrone 30, 32
- molecular mechanisms  
54, 99, 103, 121, 144, 145, 144, 145, 147, 161, 183
- molecular profiling 47, 54, 55, 88, 103, 124, 144  
in clinical trials 39  
epidemiological 104, 116  
*see also biomarkers*
- monoclonal antibodies 34, 41, 42, 55, 89  
*see also specific drug names*
- Monte Carlo simulation 175
- mortality reduction *see specific treatments, cancer types*
- mucositis 33
- myo-inositol 44
- N**
- natural killer cells 149, 158, 159, 160
- natural killer receptor genes 149, 160
- nausea 168
- near infrared (NIR) wavelengths 134  
*see also imaging*
- nematode worms 100
- neurofibromatosis 53
- Notch gene 149, 157
- Notch signaling 47, 52, 54, 143, 144, 157, 159
- nuclear medicine 32
- nurses, cancer risks of 111, 118
- nutrition 75, 82, 116, 171  
*see also diet*
- O**
- OC 144-093 44
- olanzapine 168
- oligonucleotides 92  
OGX-011 23, 26, 31, 38, 43  
G3139 30, 31, 41, 44
- ondansetron 73
- optical coherence tomography (OCT) 134, 138
- oral cancer  
detection 10, 108, 113, 114, 117, 132, 134  
genetics 112, 113, 116, 125, 130, 132  
prevention 137
- oral premalignant lesions 113, 114, 116, 126, 134, 137
- organochlorines 54, 104, 117
- organogenesis 100, 124, 142, 157
- OSI-774 (tarceva) 29, 42, 43
- OSI-779 45
- ovarian cancer  
detection 9, 184
- drug therapy 40-41
- genetics 52, 114, 124
- laboratory research 183
- phase 1 trials 184
- prevention 104, 116
- oxaliplatin 27, 28
- P**
- Paclitaxel 24, 25, 30, 41, 42, 43
- pain management 44, 164, 183
- palifermin 70
- palliative care 75, 76, 81, 82, 83, 164, 166, 168, 169, 184
- pancreatic cancer  
drug therapy 29-30  
fibroblast proteins 91  
laboratory research 121-22  
research network 86
- Panitumumab 27
- Pap test 57
- Paradigm of the Living Laboratory 4
- pathology 47-55
- pediatric cancer 108, 111, 112, 117, 148, 149
- pemetrexed 39
- peptide, blocking 124
- peptide, Notch 143
- peritoneal cancer 42
- pertuzumab (Omnitarg) 23, 41
- PET (positron emission tomography)  
23, 35, 63, 73, 86, 88, 89, 133-38, 183  
18F-FDG 73
- PFIC2 132
- P-glycoprotein 132
- pharmacoeconomics 20
- pharmacogenomics 85, 123, 129, 136
- pharmacokinetics  
in clinical trials 32, 37, 39  
in laboratory 90, 99
- Pharmacy Drug Mart 20
- pharmacocyclics 144
- phase 1 clinical trials 42-44, 85, 155
- photodynamic therapy 133, 138  
in BMT 34, 36, 37
- photoimmune therapy 36, 137
- polyohenon E 38
- population studies 13, 62, 179  
demographics 76, 98, 102, 107, 113, 117  
gene frequencies 53, 102, 114, 131  
infection frequencies 104  
profile comparisons 39, 100, 134  
tissue bank 8, 47, 100, 182
- post-treatment 84, 108, 176
- prednisolone 32
- prednisone 30, 31, 37

- prevention 57-62, 107, 130  
 chemoprevention 39, 44, 133, 137, 138  
 genetic factors 52, 55, 103, 115  
 laboratory research 121, 123, 130  
 lifestyle factors 104, 111, 113, 114, 115, 118, 119, 163, 167  
 recurrence 28, 69, 70, 79, 184
- prostate cancer  
 diet therapy 69  
 drug therapy 30-32, 69, 105, 175, 183  
 genetics 53, 97, 99, 104, 124, 148  
 laboratory research 121-22, 124, 132, 183  
 phase 1 trials 43  
 prevention 69-70, 71, 79, 97, 99, 105, 114, 118, 121-22  
 prognosis 99, 104, 113  
 quality of life 182  
 radiotherapy 69, 71-73, 182, 184  
 sociobehavioural research 80, 81, 118
- protein sequencing 99
- proteomics 47, 97, 104, 116, 124, 130, 137, 139, 144
- ps-341 35
- PSSCAN (psychosocial screening) 76, 176
- psychosocial research 75, 81, 118, 166, 175-77
- PTK787/ZK 222584 32
- pyrimidine analogues 143
- Q**
- quality of life 14, 27, 33, 83, 119, 168, 182, 183  
 sociobehavioural research 75, 119, 168, 171, 176
- R**
- Rad001c 25, 30
- radiation  
 ultraviolet 54, 104, 105, 117, 118  
 workplace 111
- radiofrequency fields 112, 117
- radiotherapy 32, 69, 141, 143, 144, 179, 184  
 prophylactic 69, 71  
 side effects 33, 182  
 simulation 175  
*see also brachytherapy, combined, conformal, intensity*
- RasGRP1 158, 161
- reflectance colour imaging 113
- renal cell cancer 32-33
- repair complexes, DNA 100, 114, 115, 124, 139, 142
- retroelements 157, 161
- revenues 15, 16, 48
- rhuMAb 2H7 37
- Rituximab 42, 44, 46
- Ro 50-3821 39
- rural areas 167, 168
- S**
- SAGE data libraries 98, 100, 105
- salivary gland cancer 112
- sarcomas 53
- satellite research centres 167
- SB-715992 29, 33
- scanning of imicrodissected archival lesions (SMAL) 126
- screening (population) 112, 113, 118  
 cultural factors 61, 79, 80, 11, 115
- Screening Mammography Program of BC 58, 118, 164, 168
- selection bias 117
- Shc 55
- SHIP protein 149, 162
- sickle cell anemia 157
- signaling 55, 125, 132, 139, 148, 158  
 lipopolysaccharide 54, 143  
*see also Notch*
- SKI-606 34
- skin cancers 108, 112  
 detection 134, 138
- social support 75, 82, 84, 112, 118, 119, 171, 174, 176
- sociobehavioural research 75-84, 167, 174
- soy 69, 71, 79
- SPARC 99
- spinocerebellar ataxia 103
- sputum analysis 134, 137
- stanford V 36
- statistics 58, 61, 107, 114, 115, 116
- stem cells 6, 51, 98, 149, 150, 158, 161, 162  
 hESC 99, 142, 156  
 plasticity 51, 142  
 technologies 99, 142, 156, 160
- stem cell transplant 37, 155
- STI 571 *see gleevec*
- strategic plan 2
- stress management 84, 176
- stromal cancer (GIST) 28-30
- SU011248 (sunitinib) 32, 33, 38
- suberoylanilide hydroxamic acid 34
- sulfasalazine 122, 124
- sulindac 39
- sun exposure 105, 118  
*see also radiation, ultraviolet*
- Sun Safe Program 58
- supportive care 27, 30, 38
- Surgical Oncology Network (SON) 59
- Surveillance and Outcomes Unit 58, 62
- Survival 62, 108, 112, 118
- symbicort turbohaler 39

- symptom management 44, 70, 73, 164  
*see also quality of life, specific symptoms*
- T**
- tamoxifen 69, 147
- Taxotere *see docetaxel*
- T-Cell transformation 158
- technology development 63, 90, 91, 102, 155, 171  
 genetics 7, 53, 98, 102, 126, 131  
 imaging 133, 138  
 molecular analysis 99, 126, 131
- telemedicine 62, 79
- telomerase gene 149, 155, 162
- telomeres 155, 160
- Temozolomide 26
- testosterone 175
- tetrodotoxin 44
- th9402 34
- thalasemia, beta 157
- thalidomide 37, 45
- therakos uvadex 36
- theralux 37
- 3D crt *see conformal*
- time of treatment 70
- tirapazamine (bendamustine) 33, 70, 139, 142
- tissue modeling 133
- tobacco 58, 164, 166, 167, 169
- topotecan 42
- transcriptional network models 158
- transfusions 39
- transgenic mouse 125
- treatment *see specific e.g. radiotherapy, combined, specific drug names and cancer types*
- tretinoin 36
- Triapine 32
- tumour microenvironment and structure 88, 89, 90, 105, 115, 139
- Tumour Tissue Repositories 8, 147, 180, 183
- tumour cell proliferation 142
- U**
- urothelial cancer 30, 42
- uterus cancer 45
- V**
- vaccines 104, 137, 179  
 liposomal 38  
 phase 1 trial 44
- valganciclovir 34
- VEGF 27, 41, 144, 175
- velcade (bortezomib) 34, 36, 37, 38
- VELScope 114, 134
- vincristine liposomes 36
- vinflunine 30
- visualization (dosimetry) *see imaging*
- vitamin D 105, 118
- W**
- workplace risk factors 111, 113, 114, 116, 117, 118
- X**
- xenografts 121, 123, 124, 136, 144, 156
- XL119 27
- Y**
- Y-ibritumomab tiuxetan 71
- youth 58, 164, 167, 169, 178, 183
- Z**
- ZD1839 (Iressa) 38, 39, 41, 70
- ZD 6474 40
- Zoledronic acid 24, 25